Sunshine Biopharma terminates Adva-27a research agreement with JGH after unfavorable lab results

Sunshine Biopharma Inc.

Termination of Research Agreement with Jewish General Hospital effective Dec 2, 2023.
Lab results on Adva-27a molecule were unfavorable, prompting termination.
IND-enabling studies of Adva-27a are paused pending chemical modification review.
Company exploring chemical modification to address suboptimal performance in certain studies.
No financial impact from termination disclosed in the filing.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Sunshine Biopharma Inc. terminated Research Agreement with Jewish General Hospital (JGH) valued at termination of Research Agreement for Adva-27a IND-enabling studies (effective 2023-12-02).

Action: termination
Agreement: collaboration
Counterparty: Jewish General Hospital (JGH)
Value: termination of Research Agreement for Adva-27a IND-enabling studies
Effective: 2023-12-02

Exact text from the filing

On November 2, 2023, the Company provided notice to JGH of its termination of the Research Agreement, which will become effective on December 2, 2023, pursuant to the terms of the Research Agreement.

View on SEC.gov

Browse all material agreements →

Sunshine Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-007582

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.